FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4367315810> ?p ?o ?g. }

• W4367315810 endingPage "1351" @default.
• W4367315810 startingPage "1351" @default.
• W4367315810 abstract "Background: Treatment of hidradenitis suppurativa (HS) is difficult and current guidelines are based mainly on expert opinion and non-randomized controlled trials. Recently, there have been some targeted therapies using uniform primary endpoints for outcome assessment. Objective: Recommendations can be provided on selecting biologics and targeted synthetic small molecules for refractory HS by comparing the efficacy and safety of these medications. Methods: Databases including ClinicalTrial.gov, Cochrane Library, and PubMed were searched. Randomized controlled trials (RCTs) for moderate-to-severe HS were eligible. We performed random-effect network meta-analysis and ranking probability. The primary outcome was Hidradenitis Suppurativa Clinical Response (HiSCR) at 12–16 weeks. Secondary outcome included Dermatology Life Quality Index (DLQI) 0/1, mean change of DLQI from baseline, and adverse effects. Results: A total of 12 RCTs involving 2915 patients were identified. Adalimumab, bimekizumab, secukinumab 300 mg q4w and secukinumab 300 mg q2w showed superiority to placebo in HiSCR at weeks 12 to 16. In addition, there was no significant difference between bimekizumab and adalimumab as measured by HiSCR (RR = 1.00; 95% CI: 0.66–1.52) and DLQI 0/1 (RR = 2.40, 95% CI: 0.88–6.50). In terms of ranking probability for achieving HiSCR at 12–16 weeks, adalimumab ranked first, followed by bimekizumab, secukinumab 300 mg q4w, and secukinumab 300 mg q2w. All biologics and small molecules did not differ in the development of adverse effects compared to placebo. Conclusions: Adalimumab, bimekizumab, secukinumab 300 mg q4w and secukinumab 300 mg q2w represent four regimens that produce better outcomes than placebo without increased risk of adverse events. Adalimumab and bimekizumab exhibited best HiSCR and DLQI 0/1 between weeks 12–16." @default.
• W4367315810 created "2023-04-29" @default.
• W4367315810 creator A5000500792 @default.
• W4367315810 creator A5042776890 @default.
• W4367315810 creator A5071598485 @default.
• W4367315810 date "2023-04-28" @default.
• W4367315810 modified "2023-09-30" @default.
• W4367315810 title "Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis" @default.
• W4367315810 cites W1617328014 @default.
• W4367315810 cites W2041193055 @default.
• W4367315810 cites W2048764846 @default.
• W4367315810 cites W2068176248 @default.
• W4367315810 cites W2149371387 @default.
• W4367315810 cites W2163545413 @default.
• W4367315810 cites W2175027747 @default.
• W4367315810 cites W2272501710 @default.
• W4367315810 cites W2503109448 @default.
• W4367315810 cites W2767737860 @default.
• W4367315810 cites W2811395800 @default.
• W4367315810 cites W2890730116 @default.
• W4367315810 cites W2891366322 @default.
• W4367315810 cites W2902268296 @default.
• W4367315810 cites W2906852571 @default.
• W4367315810 cites W2922904048 @default.
• W4367315810 cites W2954442944 @default.
• W4367315810 cites W2970684805 @default.
• W4367315810 cites W2979544789 @default.
• W4367315810 cites W3009526876 @default.
• W4367315810 cites W3028844636 @default.
• W4367315810 cites W3087112323 @default.
• W4367315810 cites W3092268290 @default.
• W4367315810 cites W3117412423 @default.
• W4367315810 cites W3118615836 @default.
• W4367315810 cites W3123328370 @default.
• W4367315810 cites W3157474078 @default.
• W4367315810 cites W3164102285 @default.
• W4367315810 cites W3185352981 @default.
• W4367315810 cites W3194448077 @default.
• W4367315810 cites W3194474366 @default.
• W4367315810 cites W3196259867 @default.
• W4367315810 cites W3216963570 @default.
• W4367315810 cites W4206317343 @default.
• W4367315810 cites W4210992315 @default.
• W4367315810 cites W4220871749 @default.
• W4367315810 cites W4281718907 @default.
• W4367315810 cites W4281749253 @default.
• W4367315810 cites W4292546850 @default.
• W4367315810 cites W4293536451 @default.
• W4367315810 cites W4311069598 @default.
• W4367315810 doi "https://doi.org/10.3390/pharmaceutics15051351" @default.
• W4367315810 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37242593" @default.
• W4367315810 hasPublicationYear "2023" @default.
• W4367315810 type Work @default.
• W4367315810 citedByCount "0" @default.
• W4367315810 crossrefType "journal-article" @default.
• W4367315810 hasAuthorship W4367315810A5000500792 @default.
• W4367315810 hasAuthorship W4367315810A5042776890 @default.
• W4367315810 hasAuthorship W4367315810A5071598485 @default.
• W4367315810 hasBestOaLocation W43673158101 @default.
• W4367315810 hasConcept C126322002 @default.
• W4367315810 hasConcept C142724271 @default.
• W4367315810 hasConcept C16005928 @default.
• W4367315810 hasConcept C168563851 @default.
• W4367315810 hasConcept C17991360 @default.
• W4367315810 hasConcept C197934379 @default.
• W4367315810 hasConcept C204787440 @default.
• W4367315810 hasConcept C27081682 @default.
• W4367315810 hasConcept C2776002364 @default.
• W4367315810 hasConcept C2776173921 @default.
• W4367315810 hasConcept C2776260265 @default.
• W4367315810 hasConcept C2776478404 @default.
• W4367315810 hasConcept C2779134260 @default.
• W4367315810 hasConcept C2779786854 @default.
• W4367315810 hasConcept C2780132546 @default.
• W4367315810 hasConcept C2780564577 @default.
• W4367315810 hasConcept C71924100 @default.
• W4367315810 hasConcept C95190672 @default.
• W4367315810 hasConceptScore W4367315810C126322002 @default.
• W4367315810 hasConceptScore W4367315810C142724271 @default.
• W4367315810 hasConceptScore W4367315810C16005928 @default.
• W4367315810 hasConceptScore W4367315810C168563851 @default.
• W4367315810 hasConceptScore W4367315810C17991360 @default.
• W4367315810 hasConceptScore W4367315810C197934379 @default.
• W4367315810 hasConceptScore W4367315810C204787440 @default.
• W4367315810 hasConceptScore W4367315810C27081682 @default.
• W4367315810 hasConceptScore W4367315810C2776002364 @default.
• W4367315810 hasConceptScore W4367315810C2776173921 @default.
• W4367315810 hasConceptScore W4367315810C2776260265 @default.
• W4367315810 hasConceptScore W4367315810C2776478404 @default.
• W4367315810 hasConceptScore W4367315810C2779134260 @default.
• W4367315810 hasConceptScore W4367315810C2779786854 @default.
• W4367315810 hasConceptScore W4367315810C2780132546 @default.
• W4367315810 hasConceptScore W4367315810C2780564577 @default.
• W4367315810 hasConceptScore W4367315810C71924100 @default.
• W4367315810 hasConceptScore W4367315810C95190672 @default.
• W4367315810 hasIssue "5" @default.
• W4367315810 hasLocation W43673158101 @default.
• W4367315810 hasLocation W43673158102 @default.

• next